These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21869689)

  • 21. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
    Du J; Zhang A; Wang L; Xuan J; Yu L; Che R; Li X; Gu N; Lin Z; Feng G; Xing Q; He L
    J Psychopharmacol; 2010 Jul; 24(7):1115-20. PubMed ID: 19395426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
    Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
    Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
    Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
    Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.
    Xing Q; Qian X; Li H; Wong S; Wu S; Feng G; Duan S; Xu M; Gao R; Qin W; Gao J; Meng J; He L
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):631-7. PubMed ID: 17105675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
    J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Ishida M; Furukori H; Kaneko S; Inoue Y; Otani K
    Pharmacogenetics; 2001 Aug; 11(6):545-50. PubMed ID: 11505224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.
    Lancelin F; Bourcier E; Le Masson V; Lemeille Y; Brovedani S; Paubel P; Piketty ML
    Ther Drug Monit; 2010 Dec; 32(6):757-61. PubMed ID: 21068648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
    Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K
    Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
    Saito M; Yasui-Furukori N; Nakagami T; Furukori H; Kaneko S
    J Clin Psychopharmacol; 2005 Dec; 25(6):527-32. PubMed ID: 16282832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.
    Zhang XR; Zhang ZJ; Zhu RX; Yuan YG; Jenkins TA; Reynolds GP
    Pharmacogenomics; 2011 Aug; 12(8):1127-36. PubMed ID: 21749219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
    Mori T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.